INmune Bio (NASDAQ:INMB) Upgraded to "Strong-Buy" at RODMAN&RENSHAW

INmune Bio (NASDAQ:INMB - Get Free Report) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other research analysts also recently issued reports about the company. Alliance Global Partners started coverage on INmune Bio in a research note on Monday, October 21st. They issued a "buy" rating and a $20.00 target price on the stock. Rodman & Renshaw assumed coverage on shares of INmune Bio in a research report on Tuesday. They issued a "buy" rating and a $23.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $20.75.

INmune Bio Price Performance

Shares of INMB traded up $0.94 during mid-day trading on Tuesday, reaching $10.16. 780,149 shares of the company's stock were exchanged, compared to its average volume of 436,913. The business's fifty day simple moving average is $5.73 and its 200-day simple moving average is $6.06. The stock has a market capitalization of $225.25 million, a PE ratio of -4.66 and a beta of 1.78. INmune Bio has a 52-week low of $4.32 and a 52-week high of $14.74.

INmune Bio (NASDAQ:INMB - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.11). During the same period in the previous year, the firm earned ($0.48) earnings per share. Equities research analysts predict that INmune Bio will post -2.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Rhumbline Advisers lifted its position in INmune Bio by 16.9% during the fourth quarter. Rhumbline Advisers now owns 16,744 shares of the company's stock worth $78,000 after buying an additional 2,424 shares during the period. Financial Advocates Investment Management increased its stake in shares of INmune Bio by 14.8% during the 4th quarter. Financial Advocates Investment Management now owns 15,500 shares of the company's stock valued at $72,000 after acquiring an additional 2,000 shares during the last quarter. Westside Investment Management Inc. lifted its holdings in shares of INmune Bio by 26.2% during the 4th quarter. Westside Investment Management Inc. now owns 89,975 shares of the company's stock worth $420,000 after acquiring an additional 18,660 shares during the period. Fermata Advisors LLC boosted its position in shares of INmune Bio by 10.0% in the fourth quarter. Fermata Advisors LLC now owns 46,997 shares of the company's stock worth $219,000 after acquiring an additional 4,267 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in shares of INmune Bio in the third quarter worth approximately $113,000. Hedge funds and other institutional investors own 12.72% of the company's stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.